Últimas noticias sobre BioNexus Gene Lab (NASDAQ:BGLC) Bolsa

BioNexus Gene Lab

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Truist Securities analyst Jasper Bibb upgrades ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) from Hold to Buy and raises the price target from $55 to $58.

News

Upgrades

Price Target

Analyst Ratings

Truist Securities Upgrades ABM Indus to Buy, Raises Price Target to $58

Tigress Financial analyst Ivan Feinseth maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $115 to $120.

Tigress Financial Maintains Buy on Walmart, Raises Price Target to $120

WIIM

ENVX

Enovix shares are trading higher after the company announced a $60 million share repurchase program.

Morgan Stanley analyst Michael Cyprys maintains WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) with a Equal-Weight and raises the price target from $9.75 to $11.

Morgan Stanley Maintains Equal-Weight on WisdomTree, Raises Price Target to $11

Barrington Research analyst Vincent Colicchio maintains Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) with a Outperform and maintains $17 price target.

ASUR

Barrington Research Maintains Outperform on Asure Software, Maintains $17 Price Target

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study
Median follow-up of 9.0 months as of the updated data cutoff
Responses observed in patients with low PD-L1 and/or CLDN18.2 expression
Company to host investor event on Tuesday, July 8th
ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO). Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register <a href="https://www.globenewswire.com/Tracker?data=1LmMD9viZ6iOkYKopeaqjzYBs1vFGdhayyfXtV3W9a-7iZIrR8MsY1dcwgYokxt8X5QJrqtfXF1YX2-GXng0F_jSogkEYNdJYD0qcbemr0g=">here</a>) to review these data.
The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S.

IMAB

I-Mab Presents Phase 1b Combination Data For Givastomig, In Combination With Nivolumab And mFOLFOX6, At ESMO GI 2025 In Barcelona

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) has outperformed the market over the past 5 years by 8.41% on an annualized basis producing an average annual return of 22.96%. Currently, Corteva has a market capitalization of $51.24 billion. 
Buying $100 In CTVA: If an investor had bought $100 of CTVA stock 5 years ago, it would be worth $277.12 today based on a price of $75.11 for CTVA at the time of writing.
<h3>Corteva's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751469392_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CTVA

Here's How Much $100 Invested In Corteva 5 Years Ago Would Be Worth Today

Morgan Stanley analyst Simeon Gutman maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Overweight and raises the price target from $50 to $70.

Morgan Stanley Maintains Overweight on Wayfair, Raises Price Target to $70

Kilroy Realty Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) near-term performance is likely to be impacted by a <a href="https://www.benzinga.com/money/what-is-a-cap-rate-in-real-estate">decline in capitalized interest</a>, according to JPMorgan.
The Kilroy Realty Analyst: Analyst Anthony Paolone maintained an Overweight rating, while cutting the price target from $42 to $40.
The Kilroy Realty Thesis: The company has been indicating less capitalized interest in 2026 for a couple quarters, Paolone said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Kilroy Oyster Point – Phase 2 (KOP II), which is Kilroy Realty&#8217;s $1.025 billion life science development in San Francisco, is currently "0% leased," he stated.
If the Street lowers estimates, it should not come as much of a surprise "since the key drags are so well known," the analyst said.
The bigger picture remains the same, including expectations of "office leasing in San Francisco, the Silicon Valley, and Seattle recovering with more tenant traffic and leases being signed in the market," he further wrote.
Price Action: Shares of Kilroy Realty had declined by 0.03% to $34.55 at the time of publication on Wednesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44613610/kilroy-realty-to-gain-from-high-quality-assets-analyst-says-stock-appears-cheap-from-real-estate-valuation-perspective">Kilroy Realty Appears Cheap From Real Estate Valuation Perspective: Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Reiteration

This Kilroy Realty Analyst Cuts Price Target On Lower Capitalized Interest, Delayed Leasing

DFDV

DeFi Development shares are trading lower after the company announced plans for a $100 million convertible notes offering.

Morgan Stanley analyst Michael Cyprys maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Underweight and raises the price target from $152 to $171.

VRTS

Morgan Stanley Maintains Underweight on Virtus Inv, Raises Price Target to $171

Morgan Stanley analyst Michael Cyprys maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Equal-Weight and raises the price target from $95 to $104.

TROW

Morgan Stanley Maintains Equal-Weight on T. Rowe Price Group, Raises Price Target to $104

<a href="https://x.com/senwarren/status/1940424688750211182?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg" title="https://x.com/senwarren/status/1940424688750211182?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/senwarren/status/1940424688750211182?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

Legal

PARA

PARAA

Elizabeth Warren Posts On X "This looks like bribery in plain sight. Paramount folded at the same time it needs Trump's approval for a billion-dollar merger. I'm calling for an investigation into whether any anti-bribery laws were broken, and I'm working on a new bill to rein in this kind of corruption."

Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) released its second-quarter 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46217973/rivian-releases-q2-2025-production-and-delivery-figures-announces-funding-of-1b-volkswagen-group-i" rel="noreferrer noopener">production and delivery results</a> on Wednesday, reflecting its continued focus on transitioning to next-generation electric vehicle models.
The company produced 5,979 vehicles between April and June and delivered 10,661 units from its Normal, Illinois, plant. Despite a planned reduction in output to prepare for its 2026 lineup, Rivian reaffirmed its full-year delivery guidance of 40,000 to 46,000 vehicles.
It also posted a second consecutive quarter of <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45236756/rivian-q1-earnings-double-beat-record-gross-profit-delivery-estimates-lowered-on-tariff-concerns" rel="noreferrer noopener">gross profit</a> in the first quarter of 2025, signaling a possible shift toward sustained profitability.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46199580/microsoft-rivian-intel-slash-jobs-in-june-tech-layoff-spree" rel="noreferrer noopener">Microsoft, Rivian, Intel Slash Jobs In June Tech Layoff Spree</a>
A major financial boost came from Volkswagen Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>), which finalized a $1 billion equity investment in Rivian on June 30. Shares were priced at $19.42 apiece, a 33% premium over Rivian&#8217;s 30-day average trading price of $14.56. The investment is part of a broader <a href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b" target="_blank" rel="noreferrer noopener">$5.8 billion</a> strategic partnership to advance EV software and platform development.
Rivian&#8217;s update comes amid a flurry of strong delivery results across the global EV sector:
<ul class="wp-block-list">
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) <a href="https://www.benzinga.com/markets/tech/25/07/46191725/nios-june-sales-surge-as-trump-casts-doubt-on-ev-future" target="_blank" rel="noreferrer noopener">reported</a> 72,056 vehicles delivered in Q2 2025, reflecting 25.6% year-over-year growth fueled by its NIO, ONVO, and FIREFLY brands.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) <a href="https://www.benzinga.com/markets/tech/25/07/46189960/tesla-rival-xpeng-records-224-surge-in-june-deliveries-crosses-2024-sales-mark-in-6-months" target="_blank" rel="noreferrer noopener">posted</a> a 224% year-over-year surge in June deliveries, with 197,189 units delivered in the first half of 2025. Already surpassing its full-year 2024 totals, this highlights a sharp acceleration in market traction.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) <a href="https://www.benzinga.com/markets/tech/25/07/46190208/li-autos-strong-q2-deliveries-mask-junes-steep-decline" target="_blank" rel="noreferrer noopener">reported</a> a 24.1% year-over-year decline in June deliveries, totaling 36,279 vehicles, pointing to mounting pressure amid shifting consumer dynamics and stronger competition.</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46221375/tesla-stock-jumps-on-strong-q2-deliveries" target="_blank" rel="noreferrer noopener">reported</a> 384,122 global deliveries in Q2 2025, including 373,728 Model 3/Y units, alongside 9.6 GWh in energy storage deployment, signaling steady growth in both automotive and energy segments.</li>
</ul>
Meanwhile, Tesla CEO Elon Musk&#8217;s threat to form a <a target="_blank" href="https://www.benzinga.com/news/politics/25/07/46216023/after-trump-warns-elon-musk-to-close-up-shop-china-rallies-behind-worlds-richest-man-theres-no-need-to-keep-putting-up-with-it" rel="noreferrer noopener">new political party</a> in response to President Donald Trump&#8217;s proposed spending bill sparked viral support on the Chinese social media platform Weibo, where users praised his anti-establishment stance. The unexpected international backing highlights Musk&#8217;s growing political influence beyond the U.S. as <a target="_blank" href="https://www.benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-more-rocket-launches-satellites-or-electric-car" rel="noreferrer noopener">tensions </a>rise over federal spending and EV-related subsidies.
Rivian plans to release its full second-quarter financial results on August 6, 2025, after the market closes.
Related ETFs include Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>) and iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>).
Price Action: RIVN shares are trading lower by 3.38% to $13.02 at Wednesday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46217895/scott-bessent-says-senators-not-threatened-by-elon-musks-words-bill-advancing-under-trumps-leadership-more-than-anybodys-checkbook" target="_blank" rel="noreferrer noopener">Scott Bessent Says Senators Not &#8216;Threatened&#8217; By Elon Musk&#8217;s Words, Bill Advancing Under Trump&#8217;s Leadership &#8216;More Than Anybody&#8217;s Checkbook&#8217;</a></li>
</ul>
Photo via Shutterstock

Guidance

Movers

DRIV

IDRV

RIVN

TSLA

VWAGY

XPEV

Rivian's Production Dips For Next-Gen Models, Volkswagen Infusion Boosts Outlook

Politics

General

Reuters Cites Constellation Brands CFO At Conf. Call, Saying Going Forward Impact Of Incremental Tariff That Went Into Effect In June To Be About $20M

Morgan Stanley analyst Keith Weiss maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Equal-Weight and raises the price target from $950 to $1040.

Morgan Stanley Maintains Equal-Weight on ServiceNow, Raises Price Target to $1040

Affirm Holdings Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fiscal 2026 revenues are likely to be impacted by Walmart Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) volumes beginning to shift to Klarna-powered OnePay in the coming quarters, as well as a higher mix of non-interest-bearing transactions, according to Needham.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5f22a54029cf490001b01b94/kyle-peterson">Analyst Kyle Peterson</a> maintained a Hold rating on the stock.
The Affirm Holdings Thesis: Despite the revenue impact, Walmart's volumes shifting to Klarna/OnePay may not affect Affirm&#8217;s operating income, as "Walmart&#8217;s traffic is less profitable than the rest of AFRM&#8217;s merchant partners,&#8221; Peterson said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Affirm Holdings should be able to retain traffic generated through its app, he added.
Non-interest-bearing transactions were around 30% of the company's GMV (gross merchandise value) in the fiscal third quarter, the analyst stated. This could "remain at an elevated rate versus recent levels as AFRM continues to prioritize consumer-friendly financing and payment options," he wrote.
While these are not long-term concerns, Affirm Holdings' stock may remain volatile as estimates are recalibrated in the coming weeks, Peterson said.
AFRM Price Action: Shares of Affirm Holdings had risen by 1.12% to $67.85 at the time of publication on Wednesday.
Read More: <a href="https://www.benzinga.com/markets/equities/25/06/46102799/us-economy-subprime-crisis-2025-household-debt-credit-card-loans-auto">Subprime Was A Trainwreck In 2008―Now It&#8217;s A Sweet Spot, Says Goldman Sachs</a>
Photo: Shutterstock

AFRM

Affirm Holdings: Impact Of Walmart-Klarna Deal, 'Higher Mix Of Zeroes'

JP Morgan analyst Anthony Paolone maintains Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) with a Overweight and lowers the price target from $42 to $40.

JP Morgan Maintains Overweight on Kilroy Realty, Lowers Price Target to $40

Morgan Stanley analyst Andrei Stadnik maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Equal-Weight and raises the price target from $33 to $36.

Janus Henderson Group plc Ordinary Shares

Morgan Stanley Maintains Equal-Weight on Janus Henderson Group, Raises Price Target to $36

Morgan Stanley analyst Michael Cyprys maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Equal-Weight and raises the price target from $15 to $16.

Morgan Stanley Maintains Equal-Weight on Invesco, Raises Price Target to $16

Financing

Press Releases

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

Comments

BioNexus Gene Lab

Noticias

Últimas noticias sobre BioNexus Gene Lab (NASDAQ:BGLC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL